Losartan Cost in New Jersey: Cash Prices, Insurance, Medicaid, and Savings in 2026

What Does Losartan Actually Cost in New Jersey in 2026?

The average cash price for a 30-day supply of generic losartan at New Jersey retail pharmacies is approximately $10 per month in 2026. Brand-name Cozaar (manufactured by Merck) carries a list price around $80 per month, though very few prescriptions are filled as brand given the wide availability of generics. Pricing varies by pharmacy, dose strength, and whether a discount card is applied.

New Jersey has over 2,700 licensed retail pharmacies, and competition among chains like CVS, Walgreens, Rite Aid, and independent pharmacies keeps generic losartan prices low. A 30-day supply of losartan 50 mg (the most commonly prescribed strength) typically ranges from $4 at large-chain pharmacy discount programs to $15 at pharmacies without discount pricing. Costco and Walmart $4 generic lists in New Jersey often include losartan at the lowest tier. The price difference between 25 mg, 50 mg, and 100 mg tablets is minimal for most generics, since manufacturing costs for different tablet strengths are nearly identical.

For patients taking the combination product losartan-hydrochlorothiazide (losartan/HCTZ), generic cash prices run slightly higher, typically $12 to $20 per month without insurance. The FDA-approved prescribing information for losartan lists doses from 25 mg to 100 mg daily for hypertension, with 50 mg as the usual starting dose [1].

New Jersey Medicaid Coverage for Losartan

New Jersey Medicaid covers losartan, but requires prior authorization (PA). The PA process typically takes 24 to 72 hours and is handled by the prescribing clinician's office. Medicaid managed care organizations (MCOs) operating in New Jersey, including Amerigroup, Aetna Better Health, Horizon NJ Health, United Healthcare Community Plan, and WellCare, each maintain their own preferred drug lists (PDLs), and losartan appears on most of them as a covered ARB.

The prior authorization requirement exists because New Jersey Medicaid PDLs often prefer certain ARBs or ACE inhibitors as first-line agents. If a patient has tried and failed the preferred agent (often lisinopril or another ACE inhibitor), the PA for losartan is typically approved without difficulty. Patients with ACE inhibitor-induced cough, a well-documented class effect affecting roughly 5% to 35% of patients according to a systematic review published in the Annals of Internal Medicine, have strong clinical justification for ARB approval [2].

For dual-eligible patients (those with both Medicare and Medicaid), losartan is covered under Medicare Part D. Most Part D plans place generic losartan on Tier 1 with copays of $0 to $5. New Jersey's Pharmaceutical Assistance to the Aged and Disabled (PAAD) program and Senior Gold Prescription Discount Program also provide losartan coverage for qualifying residents aged 65 and older with incomes below program thresholds.

Insurance Coverage Across New Jersey Plans

Nearly every commercial insurance plan sold in New Jersey covers generic losartan. The drug sits on Tier 1 (preferred generic) of formularies from Horizon Blue Cross Blue Shield of New Jersey, AmeriHealth, Cigna, Aetna, and UnitedHealthcare. Typical copays for Tier 1 generics in New Jersey plans range from $0 to $15 per month.

Patients with high-deductible health plans (HDHPs) pay cash price until their deductible is met. For these patients, the $10 average cash price for losartan means the drug remains affordable even during the deductible phase. Using a discount card alongside an HDHP is permissible, though the discounted amount may not count toward the deductible depending on the plan.

The Affordable Care Act (ACA) marketplace plans sold through GetCovered.NJ.gov must cover at least one drug in every United States Pharmacopeia (USP) category. ARBs are a required category, and losartan (as the most widely prescribed ARB) appears on every ACA marketplace formulary in New Jersey. Patients enrolling during open enrollment or a special enrollment period can verify losartan coverage by checking the plan's formulary on the GetCovered.NJ.gov website before selecting a plan.

Why Losartan Is Prescribed: Clinical Evidence

Losartan earned FDA approval in 1995 for hypertension and has since gained approvals for diabetic nephropathy in type 2 diabetes and stroke risk reduction in patients with hypertension and left ventricular hypertrophy. The evidence base supporting these indications is strong.

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension), published in The Lancet in 2002, randomized 9,193 patients aged 55 to 80 with hypertension and electrocardiographic evidence of left ventricular hypertrophy to losartan-based or atenolol-based treatment [3]. Over a mean follow-up of 4.8 years, losartan reduced the composite endpoint of cardiovascular death, stroke, and myocardial infarction by 13% compared to atenolol (relative risk 0.87, P=0.021). The stroke reduction was particularly pronounced: losartan cut fatal and non-fatal stroke risk by 25% (P=0.001).

For diabetic nephropathy, the RENAAL trial (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) enrolled 1,513 patients with type 2 diabetes and nephropathy [4]. Losartan 50 to 100 mg daily reduced the risk of doubling of serum creatinine by 25% and end-stage renal disease by 28% compared to placebo over a mean 3.4-year follow-up. Both groups received conventional antihypertensive therapy (excluding ACE inhibitors and other ARBs).

The 2017 ACC/AHA Hypertension Guideline recommends ARBs (including losartan) as first-line therapy for hypertension, particularly in patients with diabetes, chronic kidney disease, or heart failure with reduced ejection fraction [5]. The guideline states: "ARBs are recommended as an alternative for patients who develop cough or angioedema with ACE inhibitors."

Compounded Losartan in New Jersey: What You Need to Know

Compounded losartan is available in New Jersey through licensed 503A compounding pharmacies. This is legal under both federal law (the Drug Quality and Security Act of 2013) and New Jersey Board of Pharmacy regulations. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, as opposed to 503B outsourcing facilities that can produce larger batches without patient-specific prescriptions.

Compounded losartan serves a specific niche. Patients who cannot swallow tablets (pediatric patients, elderly patients with dysphagia, patients with nasogastric tubes) may need a liquid suspension. While Merck's branded losartan oral suspension exists, it is expensive and not always stocked. A compounding pharmacy can prepare a losartan oral suspension at a concentration tailored to the patient's dose, often at lower cost.

The New Jersey Board of Pharmacy requires 503A pharmacies to hold a valid NJ pharmacy license and comply with USP <795> compounding standards. Patients should verify that any compounding pharmacy they use is licensed through the New Jersey Division of Consumer Affairs. Compounded medications are not FDA-approved products, and patients should discuss the risks and benefits with their prescriber.

Pricing for compounded losartan suspensions in New Jersey varies widely, from $15 to $45 per month depending on concentration, volume, and the pharmacy. Some compounding pharmacies accept insurance, though many do not, and prior authorization requirements may differ from those for manufactured tablets.

Telehealth Prescribing of Losartan in New Jersey

New Jersey permits telehealth prescribing of losartan. The state's Telehealth Act (P.L. 2017, c.117) authorizes licensed healthcare providers to prescribe medications via audio-visual telehealth encounters. Losartan, as a non-controlled substance, faces no additional telehealth prescribing restrictions beyond standard prescribing requirements.

Several telehealth platforms operating in New Jersey can prescribe losartan for hypertension management. A typical telehealth visit for blood pressure management costs $30 to $75 without insurance. Patients need a recent blood pressure reading (home monitors are acceptable for follow-up visits) and baseline labs including a basic metabolic panel to check potassium and kidney function before starting an ARB.

New Jersey's telehealth parity law requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. Medicaid MCOs in New Jersey also cover telehealth visits. This means the telehealth visit itself, not just the medication, is a covered benefit for insured patients.

Patients starting losartan via telehealth should expect follow-up lab work (serum potassium and creatinine) within one to two weeks of initiation, per standard clinical practice. The National Kidney Foundation guidelines recommend checking potassium and renal function within two weeks of starting or dose-adjusting any RAAS inhibitor [6].

Discount Programs and Savings Strategies

Multiple pathways exist to reduce losartan costs for New Jersey residents. The most effective strategies depend on insurance status.

For uninsured patients: Pharmacy discount cards (GoodRx, RxSaver, SingleCare) can drop the cash price of generic losartan to $3 to $8 per month at New Jersey pharmacies. These cards are free to use and require no enrollment. Large chain pharmacies like Walmart, Costco, and certain ShopRite locations in New Jersey include losartan on their $4 generic programs for a 30-day supply.

For underinsured patients with high copays: Manufacturer savings cards for brand-name Cozaar may reduce copays, though the value is limited since generic losartan is already inexpensive. The savings card programs from generic manufacturers do not typically exist because the drug is already priced low.

For Medicare Part D patients: The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) means losartan costs contribute minimally to annual drug spending. Most Part D plans charge $0 to $5 for Tier 1 generics. The Medicare Part D Extra Help (Low-Income Subsidy) program eliminates or reduces copays for qualifying beneficiaries.

For NJ state program participants: The NJ PAAD program covers losartan with a $5 copay for eligible seniors. The Senior Gold program provides a 50% discount on covered prescriptions for seniors with slightly higher incomes.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic losartan with transparent markup pricing. Their model charges manufacturer cost plus a 15% margin plus a $5 pharmacy fee plus $5 shipping, which for losartan typically results in prices comparable to or slightly higher than the best discount card prices at local pharmacies. The advantage is price transparency and consistency.

How Losartan Compares to Other ARBs on Cost in New Jersey

Losartan is the least expensive ARB available in New Jersey. A cost comparison of common ARBs at NJ retail pharmacies (30-day supply, cash price, 2026 estimates) provides useful context for prescribers and patients considering alternatives.

Generic losartan 50 mg runs approximately $10 per month. Generic valsartan 80 mg costs $12 to $18. Generic irbesartan 150 mg runs $15 to $25. Generic olmesartan 20 mg costs $12 to $20. Branded azilsartan (Edarbi) remains significantly more expensive at $200 or more per month without insurance.

From a clinical perspective, the choice between ARBs often depends on indication and patient response rather than cost. Losartan has the largest evidence base for stroke prevention (LIFE trial) and diabetic nephropathy (RENAAL trial) [3][4]. Valsartan has strong heart failure data from Val-HeFT and VALIANT [7][8]. For most patients starting ARB therapy, losartan offers the best combination of clinical evidence and affordability.

The 2017 ACC/AHA guideline does not preferentially recommend one ARB over another for uncomplicated hypertension, noting that "the choice of a specific ARB may be guided by cost, patient preference, and specific indications" [5].

Potassium Monitoring and Hidden Costs

One cost often overlooked in discussions of losartan affordability is lab monitoring. All ARBs, including losartan, carry a risk of hyperkalemia (elevated potassium). The FDA label reports hyperkalemia in approximately 1.5% of losartan-treated patients in clinical trials [1].

Standard practice calls for a basic metabolic panel (BMP) before starting losartan and again one to two weeks after initiation or dose changes. A BMP costs $15 to $50 at most New Jersey labs without insurance. Quest Diagnostics and Labcorp, both with extensive New Jersey networks, offer self-pay BMP pricing in this range. Insured patients typically pay $0 to $20 depending on their plan.

Patients on losartan should budget for two to four lab draws per year during stable therapy. This adds $60 to $200 annually to the true cost of losartan therapy for uninsured patients. Telehealth-based prescribing platforms sometimes include lab orders in their visit fee, while others charge separately.

Patients at higher risk for hyperkalemia (those with chronic kidney disease, diabetes, or concurrent potassium-sparing diuretic use) may need more frequent monitoring. The combination of losartan with an ACE inhibitor (dual RAAS blockade) is generally avoided due to increased hyperkalemia risk, as demonstrated in the ONTARGET trial (N=25,620) [9].